US Pharma MarketingViatris to make $1.65B Pacira acquisition, adding to momentum in pain
Viatris acquires Pacira BioSciences for $1.65B, gaining non-opioid pain drugs Exparel and Zilretta, as pain treatment focus grows among drugmakers. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in…
Viatris, a generics and branded medicines maker, is buying into non-opioid pain drugs with a cash acquisition of commercial-stage Pacira BioSciences.
The Thursday morning deal, valued at $1.65 billion, follows a ...
Source: Endpoints News